NeoGenomics/$NEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NeoGenomics
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Ticker
$NEO
Sector
Primary listing
Employees
2,200
Headquarters
Website
NeoGenomics Metrics
BasicAdvanced
$1.2B
-
-$0.82
1.62
-
Price and volume
Market cap
$1.2B
Beta
1.62
52-week high
$19.12
52-week low
$4.72
Average daily volume
3M
Financial strength
Current ratio
3.921
Quick ratio
3.164
Long term debt to equity
47.739
Total debt to equity
48.214
Interest coverage (TTM)
-13.57%
Profitability
EBITDA (TTM)
-7.776
Gross margin (TTM)
43.85%
Net profit margin (TTM)
-15.10%
Operating margin (TTM)
-11.45%
Effective tax rate (TTM)
1.34%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-3.25%
Return on equity (TTM)
-11.76%
Valuation
Price to revenue (TTM)
1.682
Price to book
1.37
Price to tangible book (TTM)
41.67
Price to free cash flow (TTM)
-60.452
Free cash flow yield (TTM)
-1.65%
Free cash flow per share (TTM)
-0.151
Growth
Revenue change (TTM)
9.70%
Earnings per share change (TTM)
31.74%
3-year revenue growth (CAGR)
12.09%
10-year revenue growth (CAGR)
21.84%
3-year earnings per share growth (CAGR)
-12.17%
10-year earnings per share growth (CAGR)
54.54%
What the Analysts think about NeoGenomics
Analyst ratings (Buy, Hold, Sell) for NeoGenomics stock.
Bulls say / Bears say
Consolidated revenue grew 10% to $181 million in Q2 2025, led by a 16% increase in clinical revenue and 23% growth in NGS services. (BusinessWire)
Cash flow from operations improved 46.3% to $20.3 million in Q2 2025, bolstering the company’s liquidity position. (Investing.com)
The April 2025 acquisition of Pathline LLC expands NeoGenomics’ lab footprint in the Northeastern U.S., enhancing service capacity and cross-selling opportunities. (BusinessWire)
Net loss widened 142% to $45 million in Q2 2025, driven by $20 million of impairment charges, exacerbating the company’s unprofitability. (BusinessWire)
Adjusted EBITDA remained flat at $10.7 million year-over-year in Q2 2025, suggesting limited margin expansion despite revenue gains. (BusinessWire)
Full-year 2025 revenue guidance was cut to $720 million–$726 million from $747 million–$759 million, signaling slower growth and potential execution hurdles. (BusinessWire) (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
NeoGenomics Financial Performance
Revenues and expenses
NeoGenomics Earnings Performance
Company profitability
NeoGenomics News
AllArticlesVideos
NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims
Benzinga1 month ago
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
Business Wire1 month ago
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NeoGenomics stock?
NeoGenomics (NEO) has a market cap of $1.2B as of October 05, 2025.
What is the P/E ratio for NeoGenomics stock?
The price to earnings (P/E) ratio for NeoGenomics (NEO) stock is 0 as of October 05, 2025.
Does NeoGenomics stock pay dividends?
No, NeoGenomics (NEO) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next NeoGenomics dividend payment date?
NeoGenomics (NEO) stock does not pay dividends to its shareholders.
What is the beta indicator for NeoGenomics?
NeoGenomics (NEO) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.